by webmaster | Mar 30, 2023 | News en
Navamedic ASA (“Navamedic”) announced on 29 March 2023 a public takeover offer to the shareholders of Sensidose Aktiebolag. Sensidose has published the following information relating to the takeover offer: For further information, please see... by webmaster | Feb 8, 2023 | News en
As part of Sensidose’s ongoing geographical expansion, the company last autumn applied for reimbursement for Flexilev with the Finnish Pharmaceutical Price Board (Lääkkeiden hintalautakunta). The application has now been granted and the approval is in accordance... by webmaster | Sep 12, 2022 | News en
The idea for Sensidose’s treatment strategy came about already in the mid-1990s when professors Sten-Magnus Aquilonius and Christer Nyström realized that it would be possible to personalise Parkinson’s treatment with microtablets. Today, the company’s drug Flexilev... by webmaster | Sep 6, 2022 | News en
Pharma company Sensidose has recruited Philip Slätis as Chief Operating Officer and Deputy CEO. Slätis takes on on his role on November 1 and brings broad experience from the pharmaceutical industry. He is expected to contribute to the company’s business development... by webmaster | Sep 1, 2022 | News en
Sollentuna 1:a September 2022 Sensidose reinforces its management. Philip Slätis has been hired as Chief Operating Officer and Deputy CEO of Sensidose AB. Philip will take up the position on 1st November in 2022. – Philips’ broad experience from all parts...